Compare VC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VC | MLYS |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.1B |
| IPO Year | 2000 | 2023 |
| Metric | VC | MLYS |
|---|---|---|
| Price | $96.83 | $37.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $129.08 | $47.33 |
| AVG Volume (30 Days) | 377.6K | ★ 1.5M |
| Earning Date | 10-23-2025 | 02-11-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 11.17 | N/A |
| Revenue | ★ $3,759,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.92 | N/A |
| P/E Ratio | $8.68 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $65.10 | $8.24 |
| 52 Week High | $129.10 | $47.65 |
| Indicator | VC | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 34.06 | 44.07 |
| Support Level | $95.99 | $36.50 |
| Resistance Level | $105.93 | $38.23 |
| Average True Range (ATR) | 2.41 | 1.68 |
| MACD | -0.26 | 0.11 |
| Stochastic Oscillator | 9.66 | 47.55 |
Visteon Corp is an automotive supplier. It manufactures electronics products for original equipment vehicle manufacturers including Ford, Nissan, Renault, Mazda, BMW, General Motors, and Honda, etc. The company offers information displays, instrument clusters, head-up displays, infotainment systems, telematics solutions, and Smartcore. The Company's reportable segment is Electronics. The Electronics segment provides vehicle cockpit electronics products to customers, including digital instrument clusters, domain controllers with integrated driver assistance systems, displays, Android-based infotainment systems, and battery management systems. Geographically, it operates in North America, Europe, China, Asia-Pacific, and South America and Others.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.